← Leaderboards
James Fraser Stoddart
University Of California Los Angeles
$522,761
Attributed
$2,091,042
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $438.8K · FY2010–14$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,091,042 · 1
By mechanism
R01$2,091,042 · 1
Top collaborators
- Andre Elias Nel8 shared
- Fuyuhiko Tamanoi8 shared
- Jeffrey I Zink8 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- David T Wong$54,826,713
- Andre Elias Nel$21,296,649
- Sanjiv S Gambhir$44,452,033
- Z Hong Zhou$29,087,466
- Fuyuhiko Tamanoi$5,574,151
Others in their field
Top investigators on “Adriamycin Pfs”
- Rujun Gong · Rhode Island Hospital$4,330,471
- Andrew D. Zelenetz · Sloan-Kettering Inst Can Research$4,323,271
- John C He · James J Peters Va Medical Center$3,518,192
- Sumant Singh Chugh · Rush University Medical Center$2,812,131
- Catherine Sibyl Diefenbach · New York University School Of Medicine$2,770,577
- Aimee Marie Crago · Sloan-Kettering Inst Can Research$2,751,471
Research focus
Adriamycin PfsAntineoplastic AgentsApoptosisAlpha BenzopyroneAzobenzeneCaliforniaCamptothecinCancer CellCancer Cell LineAqueousCancer TherapyCapsule (Pharmacologic)Cell DeathCell LineCell MembraneCellsChemotherapeutic AgentChemotherapy-Oncologic ProcedureConfocal MicroscopyConstitutionControlled ReleaseCoumarinsDesignDna Binding
Grant awards (8)
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$380,516
R01 · FY2014 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$22,823
R01 · FY2014 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$369,346
R01 · FY2013 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$64,637
R01 · FY2013 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$393,575
R01 · FY2012 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$45,234
R01 · FY2012 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$394,252
R01 · FY2011 · CA
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$420,659
R01 · FY2010 · CA